Clinical implications of mutational analysis in gastrointestinal stromal tumours

por Hoeben, A, Schöffski, P, Debiec-Rychter, M
Publicado 2008

Identity of tumorigenic human urothelial cell lines and 'spontaneously' transformed sublines.

por Christensen, B., Hansen, C., Debiec-Rychter, M., Kieler, J., Ottensen, S., Schmidt, J.
Publicado 1993

A phase II trial with rosiglitazone in liposarcoma patients

por Debrock, G, Vanhentenrijk, V, Sciot, R, Debiec-Rychter, M, Oyen, R, Van Oosterom, A
Publicado 2003

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

por Widmer, N, Decosterd, L A, Leyvraz, S, Duchosal, M A, Rosselet, A, Debiec-Rychter, M, Csajka, C, Biollaz, J, Buclin, T
Publicado 2008

MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours

por Gits, C M M, van Kuijk, P F, Jonkers, M B E, Boersma, A W M, van IJcken, W F, Wozniak, A, Sciot, R, Rutkowski, P, Schöffski, P, Taguchi, T, Mathijssen, R H J, Verweij, J, Sleijfer, S, Debiec-Rychter, M, Wiemer, E A C
Publicado 2013